Medeor Therapeutics Inc Information

Medeor Therapeutics is a clinical-stage biotechnology company dedicated to discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients and patients that suffer from hematologic conditions. Medeor's product candidates each comprise a unique composition of different types of hematopoietic donor-derived cells, based on breakthrough technologies discovered at Stanford University and exclusively licensed by Medeor. These product candidates are designed to produce mixed chimerism, the co-existence of both recipient and donor blood and immune cells in the recipient. For organ transplant patients, mixed chimerism can induce donor-specific immune tolerance, which reduces the likelihood of transplant organ loss, reduces or eliminates chronic immunosuppressive drug therapy, and thereby improves patient outcomes. For hematologic conditions, mixed chimerism has the potential to reduce or eliminate disease symptoms.